,37 Of importance, SGLT2 inhibitor therapy for CKD was likely underestimated in this study because the entire patient population with type 2 diabetes was included rather than patients with type 2 diabetes, eGFR ≥20 mL/min/1.73 m2 and uACR >200 mg/g, which are the kidney disease indications for SGLT2i use according to current ADA recommendations.18 This evidence concerns the gene SLC5A2 and kidney disorder.